 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
A Comparison of Two Methods of Starting the Anticoagulant Drug Warfarin
6 May 2003 | Volume 138 Issue 9 | Page I-50
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular- Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. A Randomized, Double-Blind, Controlled Trial." It is in the 6 May 2003 issue of Annals of Internal Medicine (volume 138, pages 714-719). The authors are M.J. Kovacs, M. Rodger, D.R. Anderson, B. Morrow, G. Kells, J. Kovacs, E. Boyle, and P.S. Wells.
What is the problem and what is known about it so far?
Acute venous thromboembolism is a condition in which blood clots form in veins. The clots most often occur in leg veins, causing pain and swelling. Pieces of these clots can break off and travel to the lung, a serious condition called pulmonary embolism. To treat acute venous thromboembolism, doctors prescribe anticoagulant drugs that make the blood take longer to clot. Treatment usually starts with the drug heparin, followed by treatment with warfarin. Heparin begins to work quickly but must be given by injection. Warfarin is taken by mouth, so it is easy for a patient to use at home. However, it can take several days after starting warfarin before the drug reaches a therapeutic level. A therapeutic level means that the blood is anticoagulated enough to treat the thromboembolism, but not too much. Too much warfarin can lead to bleeding complications. Doctors use a test called the international normalized ratio (INR) to see whether a person is taking the correct amount of warfarin. The correct dose varies greatly from patient to patient. The best starting dose is not clear, but many doctors start with 5 mg of warfarin. A higher starting dose might achieve a therapeutic level more quickly.
Why did the researchers do this particular study?
To see whether patients would achieve a therapeutic level of warfarin more quickly with a dosing method that starts with 10 mg of warfarin than one that starts with a 5-mg dose.
Who was studied?
201 outpatients with acute venous thromboembolism seen at one of four Canadian hospitals.
How was the study done?
The researchers assigned patients at random to begin warfarin therapy using a 5-mg starting dose strategy or a 10-mg starting dose strategy. They then saw how long it took for patients in each group to reach a therapeutic INR level. The researchers treated all patients initially with at least 5 days of a type of heparin called low-molecular-weight heparin.
What did the researchers find?
Patients in the group treated with the dosing regimen that started with 10 mg achieved a therapeutic INR 1.4 days sooner than patients in the 5-mg group. The patients in the 10-mg group also required fewer INR tests. There was no difference in bleeding complications between the two groups.
What were the limitations of the study?
This study involved only patients who were being treated as outpatients. The results may not apply to patients in the hospital. Doctors may get the same results in their outpatients only if they use exactly the same warfarin dosing strategy as the researchers used, which is more complicated than simply starting with a 10-mg initial dose.
What are the implications of the study?
Doctors should consider using the 10-mg starting dose method if they are interested in having patients achieve a therapeutic level of warfarin quickly.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  D. A Garcia, D. M Witt, E. Hylek, A. K Wittkowsky, E. A Nutescu, A. Jacobson, S. Moll, G. J Merli, M. Crowther, L. Earl, et al. Delivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation Forum Ann. Pharmacother., July 1, 2008; 42(7): 979 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 160S - 198S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, B. D. Horne, S. M. Stevens, A. S. Grove, S. Barton, Z. P. Nicholas, S. F.S. Kahn, H. T. May, K. M. Samuelson, J. B. Muhlestein, et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation Circulation, November 27, 2007; 116(22): 2563 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A Lenzini, G. R Grice, P. E Milligan, S. K Gatchel, E. Deych, C. S Eby, R S. J Burnett, J. C Clohisy, R. L Barrack, and B. F Gage Optimal Initial Dose Adjustment of Warfarin in Orthopedic Patients Ann. Pharmacother., November 1, 2007; 41(11): 1798 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Millican, P. A. Lenzini, P. E. Milligan, L. Grosso, C. Eby, E. Deych, G. Grice, J. C. Clohisy, R. L. Barrack, R. S. J. Burnett, et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood, September 1, 2007; 110(5): 1511 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Krynetskiy and P. McDonnell Building Individualized Medicine: Prevention of Adverse Reactions to Warfarin Therapy J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Dager and M. P. Gulseth Implementing anticoagulation management by pharmacists in the inpatient setting Am. J. Health Syst. Pharm., May 15, 2007; 64(10): 1071 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Forster Can you prevent adverse drug events after hospital discharge? Can. Med. Assoc. J., March 28, 2006; 174(7): 921 - 922. [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Messmore, J. Fareed, and R. L. Bick Pitfalls in Warfarin Therapy Clinical and Applied Thrombosis/Hemostasis, January 1, 2006; 12(1): 1 - 2. [PDF]
|
|
|
|
|
|
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Haines and E. A. Nutescu Current and emerging treatment options for venous thrombosis: A case discussion Am. J. Health Syst. Pharm., March 15, 2005; 62(6): 593 - 605. [Full Text] [PDF]
|
|
|
|
|
|
C. D Eckhoff, R. J DiDomenico, and N. L Shapiro Initiating Warfarin Therapy: 5 mg versus 10 mg Ann. Pharmacother., December 1, 2004; 38(12): 2115 - 2121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McGuire and P. P. Dobesh Therapeutic Update on the Prevention and Treatment of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 289 - 307. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]
|
|
|
|
|
|
J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 204S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Buller, G. Agnelli, R. D. Hull, T. M. Hyers, M. H. Prins, and G. E. Raskob Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 401S - 428S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. McRae and J. S. Ginsberg Initial Treatment of Venous Thromboembolism Circulation, August 31, 2004; 110(9_suppl_1): I-3 - I-9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kroenke and L. Logio Update in General Internal Medicine Ann Intern Med, August 3, 2004; 141(3): 213 - 220. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Errichi, M. R. Cesarone, G. Belcaro, R. Marinucci, A. Ricci, A. Ippolito, R. Brandolini, G. Vinciguerra, M. Dugall, A. Felicita, et al. Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry Angiology, May 1, 2004; 55(3): 243 - 249. [Abstract] [PDF]
|
|
|
|
|
|
G. M. Peterson and S. L. Jackson Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 488 - 488. [Full Text] [PDF]
|
|
|
|
|
|
R. Zeller Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 489 - 489. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Crowther, L. Harrison, and J. Hirsh Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 490 - 490. [Full Text] [PDF]
|
|
|
|
|
|
K. L. McCall Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 491 - 491. [Full Text] [PDF]
|
|
|
|
|
|
R. White and W. Dager Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 488 - 489. [Full Text] [PDF]
|
|
|
|
|
|
B. F. Gage Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 489 - 489. [Full Text] [PDF]
|
|
|
|
|
|
R. J. DiDomenico Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 489 - 490. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin Randomized Trial of Warfarin Nomograms Ann Intern Med, March 16, 2004; 140(6): 490 - 491. [Full Text] [PDF]
|
|
|
|
|
|
L.-A. Linkins, P. T. Choi, and J. D. Douketis Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 893 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Itskowitz and S. Schulman Long-Term Anticoagulant Therapy N. Engl. J. Med., November 13, 2003; 349(20): 1976 - 1977. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J Beyth A 10 mg nomogram was more effective than a 5 mg nomogram for warfarin induction in outpatient venous thromboembolism Evid. Based Med., November 1, 2003; 8(6): 173 - 173. [Full Text] [PDF]
|
|
|
|
 |
|
 OTHER ARTICLES NOTED (25 Apr 2003 to 18 Jul 2003) Evid. Based Nurs., October 1, 2003; 6(4): e1 - 12. [Full Text]
|
|
|
|
 |
|
 Outpatient Acute VTE -- What's the Best Treatment Strategy? Journal Watch Cardiology, July 18, 2003; 2003(718): 2 - 2. [Full Text]
|
|
|
|
 |
|
 Starting Dose of Warfarin for Outpatient DVT Treatment Journal Watch Emergency Medicine, June 10, 2003; 2003(610): 2 - 2. [Full Text]
|
|
|
|
 |
|
 10-mg or 5-mg Warfarin Loading for Outpatients with VTE? Journal Watch (General), May 20, 2003; 2003(520): 4 - 4. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
